![William Skelly](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
William Skelly
Director/Board Member at
ACURA PHARMACEUTICALS, INC.
Net worth: 676 $ as of 2026-04-29
Profile
William G.
Skelly is Chairman, President & Chief Executive Officer at Central Biomedia, Inc. since 1990.
Mr. Skelly is Chairman, President & Chief Executive Officer at SERA, Inc. since 1990.
Mr. Skelly is Independent Director at Acura Pharmaceuticals, Inc. since 2000.
Mr. Skelly was President at Martec Pharmaceutical, Inc. from 1985 to 1990.
Mr. Skelly completed undergraduate studies at Michigan State University.
Mr. Skelly earned an MBA from the University of Missouri-Kansas City.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-01-01 | 675,989 ( 1.02% ) | 676 $ | 2026-04-29 |
William Skelly active positions
| Companies | Position | Start |
|---|---|---|
| ACURA PHARMACEUTICALS, INC. | Director/Board Member | 2000-05-31 |
SERA, Inc.
 SERA, Inc. Investment ManagersFinance Part of Central Biomedia, Inc., SERA, Inc. is a company that specializes in competitive immunotherapy products designed to prevent failure of passive transfer (FPT) in foals. The company is based in Shawnee Mission, KS. The company's flagship product, Seramune®, is an all-natural, concentrated equine serum administered orally shortly after birth to enhance passive immunity and reduce risks of infections such as gastrointestinal distress and pneumonia. Seramune® delivers approximately 30 grams of IgG per dose, is USDA licensed, sterile filtered, gamma irradiated, refrigerated (not frozen), and has a three-year shelf life. It is produced by pooling serum from multiple geldings without additives or preservatives and offers a higher IgG concentration compared to standard plasma products. SERA emphasizes cost-effective prophylactic immunotherapy to improve foaling outcomes and provides detailed product information, distributor networks, and technical guidance through its website. William G. Skelly has been the CEO of the company since 1990. | Chief Executive Officer | 1989-12-31 |
Central Biomedia, Inc.
 Central Biomedia, Inc. BiotechnologyHealth Technology Manufactures private-labeled animal serum | Chief Executive Officer | 1989-12-31 |
Former positions of William Skelly
| Companies | Position | End |
|---|---|---|
Martec Pharmaceutical, Inc. | President | 1989-12-31 |
Training of William Skelly
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
17
1st degree connections
6
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Acura Pharmaceuticals, Inc.
 Acura Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes pharmaceutical ingredients | Health Technology |
Michigan State University
 Michigan State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Central Biomedia, Inc.
Central Biomedia, Inc. BiotechnologyHealth Technology Manufactures private-labeled animal serum | Health Technology |
SERA, Inc.
SERA, Inc. Investment ManagersFinance Part of Central Biomedia, Inc., SERA, Inc. is a company that specializes in competitive immunotherapy products designed to prevent failure of passive transfer (FPT) in foals. The company is based in Shawnee Mission, KS. The company's flagship product, Seramune®, is an all-natural, concentrated equine serum administered orally shortly after birth to enhance passive immunity and reduce risks of infections such as gastrointestinal distress and pneumonia. Seramune® delivers approximately 30 grams of IgG per dose, is USDA licensed, sterile filtered, gamma irradiated, refrigerated (not frozen), and has a three-year shelf life. It is produced by pooling serum from multiple geldings without additives or preservatives and offers a higher IgG concentration compared to standard plasma products. SERA emphasizes cost-effective prophylactic immunotherapy to improve foaling outcomes and provides detailed product information, distributor networks, and technical guidance through its website. William G. Skelly has been the CEO of the company since 1990. | Finance |
Martec Pharmaceutical, Inc. | |
University of Missouri-Kansas City
 University of Missouri-Kansas City Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- William Skelly
